Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors

“Pachyonychia congenita (PC) is a life-altering genetic disease which dramatically limits patients’ ability to ambulate and perform everyday functional activities,” stated Dr. Heron. “Palvella’s lead program PTX‑022 (novel, high-strength rapamycin topical formulation, optimized for dermal targeting) has significant potential to address this serious unmet need that currently has no approved treatments. I look forward to applying my background in rare diseases in supporting Palvella’s efforts to advance PTX-022 through late stage clinical development and commercialization.”

Read the full press release.

PC News and Events

Click here for PC Project News and Events webpage which includes announcements of upcoming events, important news information as well as links to all PC Patient NewsBrief issues and IPCC Newsletter issues.
PC Patient Registry
Learn why this international registry of PC patients is so crucial to the worldwide efforts to find treatments and a cure for PC